Systematic review reveals psilocybin reduces obsessive-compulsive behaviors across clinical and preclinical evidence
Genomic PressPeer-Reviewed Publication
A comprehensive systematic review published today in Psychedelics examines psilocybin's therapeutic potential for obsessive-compulsive disorder and related conditions, synthesizing evidence from four clinical trials and nine preclinical investigations. The analysis, led by James J. Gattuso from the Florey Institute of Neuroscience and Mental Health at the University of Melbourne, reveals that psilocybin produces rapid reductions in obsessive-compulsive symptoms in clinical populations and sustained anti-compulsive effects in validated animal models. The review identifies consistent therapeutic patterns across species while highlighting critical knowledge gaps, including the need for larger placebo-controlled trials and mechanistic neuroimaging studies. The synthesis demonstrates that psilocybin's anti-compulsive effects may occur independently of its hallucinogenic properties, suggesting potential for non-psychedelic therapeutic approaches. This systematic analysis provides researchers, clinicians, and policymakers with the first comprehensive framework for understanding psilocybin's role in treating the full spectrum of obsessive-compulsive and related disorders.
- Journal
- Psychedelics
- Funder
- National Health and Medical Research Council, University of Melbourne, Victorian Government, University of Melbourne